{{Rsnum
|rsid=3824886
|Gene=HTATIP2
|Chromosome=11
|position=20383067
|Orientation=plus
|ReferenceAllele=T
|MissenseAllele=G
|GMAF=0.2888
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=HTATIP2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 92.3 | 7.7 | 0.0
| HCB | 25.0 | 47.7 | 27.3
| JPT | 14.0 | 60.5 | 25.6
| YRI | 36.5 | 55.6 | 7.9
| ASW | 0.0 | 0.0 | 0.0
| CHB | 25.0 | 47.7 | 27.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{Venter SNP
|rsid=3824886
|allele=G
|frequency=0.958
|uid=1103649625796
|type=homozygous_SNP
|hugo=HTATIP2
|ensembl gene=ENSG00000109854
|ensembl transcript=ENST00000338653
|sift=TOLERATED
|disease=Defects in HTATIP2 are a cause of aggressive metastatic proliferation in variant small cell lung carcinomas (vSCLC). Furthermore, they are associated with 33% of hepatocellular carcinomas (HCC). Lack of HTATIP2 renders tumor cells resistant to apoptotic signals.
}}

{{PMID Auto
|PMID=16251468
|Title=Survey of allelic expression using EST mining.
|OA=1
}}

{{GET Evidence
|gene=HTATIP2
|aa_change=Ser231Arg
|aa_change_short=S231R
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3824886
|overall_frequency_n=9071
|overall_frequency_d=10758
|overall_frequency=0.843186
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=80
|n_articles=0
|n_articles_annotated=0
|nblosum100=3
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}